Organogenesis Holdings Inc.ORGOEarnings & Financial Report
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
Revenue
$126.7M
Gross Profit
$95.6M
Operating Profit
$10.2M
Net Profit
$7.7M
Gross Margin
75.5%
Operating Margin
8.1%
Net Margin
6.1%
YoY Growth
27.1%
EPS
$0.05
Organogenesis Holdings Inc. Q4 FY2024 Financial Summary
Organogenesis Holdings Inc. reported revenue of $126.7M (up 27.1% YoY) for Q4 FY2024, with a net profit of $7.7M (up 1448.5% YoY) (6.1% margin). Cost of goods sold was $31.1M, operating expenses totaled $85.4M.
Key Financial Metrics
| Total Revenue | $126.7M |
|---|---|
| Net Profit | $7.7M |
| Gross Margin | 75.5% |
| Operating Margin | 8.1% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Organogenesis Holdings Inc. Q4 FY2024 revenue of $126.7M breaks down across 2 segments, led by Advanced Wound Care at $118.6M (93.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Advanced Wound Care | $118.6M | 93.6% |
| Surgical And Sports Medicine | $8.1M | 6.4% |
Organogenesis Holdings Inc. Annual Revenue by Year
Organogenesis Holdings Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $564.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $564.2M |
| 2024 | $482.0M |
| 2023 | $433.1M |
| 2022 | $450.9M |
Organogenesis Holdings Inc. Quarterly Revenue & Net Profit History
Organogenesis Holdings Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $37.2M | -57.1% | N/A | N/A |
| Q4 FY2025 | $225.6M | +78.1% | $43.7M | 19.4% |
| Q3 FY2025 | $150.9M | +31.0% | $21.6M | 14.3% |
| Q2 FY2025 | $101.0M | -22.4% | $-9.4M | -9.3% |
| Q1 FY2025 | $86.7M | -21.2% | $-18.8M | -21.7% |
| Q4 FY2024 | $126.7M | +27.1% | $7.7M | 6.1% |
| Q3 FY2024 | $115.2M | +6.1% | $12.3M | 10.7% |
| Q2 FY2024 | $130.2M | +11.0% | $-17.0M | -13.1% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $130.2M | $115.2M | $126.7M | $86.7M | $101.0M | $150.9M | $225.6M | $37.2M |
| YoY Growth | 11.0% | 6.1% | 27.1% | -21.2% | -22.4% | 31.0% | 78.1% | -57.1% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $443.2M | $446.3M | $497.9M | $467.4M | $461.1M | $509.8M | $598.7M | $520.0M |
| Liabilities | $179.7M | $167.7M | $112.6M | $99.3M | $99.9M | $123.8M | $164.8M | $138.6M |
| Equity | $263.5M | $278.5M | $262.9M | $242.9M | $233.2M | $255.1M | $300.1M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $4.7M | $8.7M | $10.9M | $-19.9M | $-32.9M | $3.1M | $39.4M |